Dutch Industry Group Extends Scope
The activities of the Dutch research-based drug industry association,Nefarma, and those of the Foundation for Advancement of Medical-Pharmaceutical Research have been integrated, with most Foundation activities now coming under Nefarma's supervision.
This development, which took effect on January 1, extends Nefarma's responsibilities into a number of new areas including health economics, clinical drug research and pharmacoepidemiology.
The Marketletter's correspondent notes that the Foundation was originally set up, by Nefarma member companies, to foster research projects in the Netherlands, with the two groups located in the same building. The significant changes which took place at Nefarma in 1996 will of course have had repercussions for the Foundation; Nefarma is still without a general manager, and with drug prices now a major problem for its members, it is stressing the value of research projects.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze